Tuesday, 16 June 2020

Physical Therapy Equipment Market 2020 Global Trend, Segmentation and Opportunities, Forecast 2025

Market Scenario:
There has been a high level of technological improvement in physical therapy equipment in the past few years, which is fueling the global market growth. Also, as physical therapy equipment is designed specifically to assist people to either regain or improve their physical abilities; thus, number of companies are investing in this market.
The Global Physical Therapy Equipment Market is expected to hold a value of USD 19,100 Million by 2025 at a CAGR of 6.21%, says Market Research Future in Physical Therapy Equipment Market Forecast 2020.
Market Influencer
The increasing initiatives by public and private companies boost market growth. The growing number of equipment launches also acquisitions and mergers of key players in the market are likely to act as a promising factor for the growth in the near future.  For instance, in February 2019, Colfax acquired DJO Global, Inc. for USD 3.15 billion. This helps Colfax to widen its product portfolio in the orthopedic segment.
Market Drivers
  • Growing prevalence of orthopedic disorders
  • Rising geriatric population
  • Rising incidence of sport injuries
  • Increasing awareness about physical therapy equipment
  • Rising incidences of road accidents
  • Huge number of R&D activities in the field of physiotherapy
  • Upsurging support by public and private companies
  • Increasing mergers and acquisitions by prominent players in the market. For instance, in April 2017, Dynatronics’s acquired Hausmann Industries, a manufacturer of branded, high-quality physical therapy and athletic training products. With this acquisition, the company aimed to increase business in the physical therapy equipment market
  • Growing government schemes promoting the use of rehabilitation equipment
Market Restraints
  • Inadequate reimbursement policies for physiotherapy
  • Lack of trained and skilled personnel
Segmentation
By Product
  • Equipment: Expected to hold the largest share, owing to the wide range of applications it offers. The type of equipment is electrotherapy equipment, ultrasound equipment, exercise therapy equipment, cryotherapy equipment, combination therapy equipment, continuous passive motion (CPM) therapy equipment, shockwave therapy equipment, laser therapy equipment, traction therapy equipment, magnetic therapy equipment, and others.
  • The use of physical therapy equipment is increased due to the global increase in orthopedic diseases. For example, approximately 80% of Americans will experience back problems at some point in their lives.  Also, an estimated 10% of the world’s population suffers from lower back pain.
  • Accessories: This is expected to be the fastest segment attributed to increasing use of physical therapy equipment for the cure of musculoskeletal diseases. The accessories segment is further divided into two types, namely, physiotherapy furniture and physiotherapy tapes and bandages.
By Application
  • Musculoskeletal Applications: Expected to hold the largest share, owing to increasing incidence of musculoskeletal disorders and also increasing the geriatric population.
  • Neurological Applications: This is expected to hold the fastest segment is attributed to an increase in prevalence of neurological diseases such as paralytic attacks and strokes.
  • Cardiovascular & Pulmonary Applications: The cardiovascular and pulmonary applications segment is witnessing significant growth due to increasing prevalence of cardiovascular diseases and chronic obstructive pulmonary disease (COPD).
  • Pediatric Applications: Increased use of physical therapy for musculoskeletal (MSK) disorders in children.
  • Gynecological Applications: The role of physiotherapy is in obstetrics and gynecology involves pregnancy, labor, and the puerperium, preoperative, and postoperative periods.
  • Others: Other applications include rehabilitation centers where the use of physical therapy is increasing.
By End-User
  • Hospitals and Clinics: Hospitals and clinics are expected to hold the largest segment due to usually a large patient pool and advanced physical therapy setups in hospitals based on the need of patients. Growing awareness about new physical therapy is projected to drive the growth of this segment during the forecast period.
  • Physiotherapy Centers: Expected to hold the fastest segment, owing to growing awareness about new physical therapy among the population.
  • Home Care Settings: Many companies launching the range of physical therapy devices available for use at home.
By Region
  • Americas: The largest regional market. Countries such as the US and Canada have well-established physical therapy centers which constitute advanced physical therapy systems and instruments. This contributes to the growth of the physical therapy equipment market in this region.
  • Europe: The Europe market is expected to hold the second-largest market due to increasing prevalence of neurological disorders, orthopedic problems coupled with cardiopulmonary diseases in the region.
  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global physical therapy equipment market. This is due to the increasing geriatric population and a large number of patients suffering from neurological diseases in China and Japan.
  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and limited exposure to technological advancements.
Key Players
  • DJO Global, Inc. (US)
  • BTL Industries (US)
  • Enraf-NoniUS B.V (Europe)
  • Dynatronics Corporation (US)
  • EMS Physio (UK)
  • ITO Co. Ltd (Japan)
  • Mectronic Medicale (Europe)
  • Performance Health (Subsidiary of Madison Dearborn Partners) (US)
  • Whitehall Manufacturing (US)
  • Zimmer Medizinsysteme GmbH (Germany)
  • Colfax Corporation (US)
  • STORZ MEDICAL (US)
Posted by at No comments:

Global Nasal Drug Delivery Market 2020 Business Insights & Deep Analysis to 2023 by World’s Top 10 Key Players

Market Scenario
The global nasal drug delivery market is expected to grow significantly over the forecast period. The global market was valued at approximately USD 52,998.5 million in 2018 and is projected to grow with 6.6% CAGR over the forecast period.
Nasal drug delivery is administration of drug through the nasal track to treat various respiratory problems such as paranasal sinuses, nasal infection, and other nasal problems. It is an effective delivery method for medicines that are active in low doses.
Factors such as the painless drug administration, development of new nasal drug delivery technology market, and the increasing number of patient population with respiratory problem are expected to drive the market growth. Moreover, nasal drug delivery devices are easily accessible and suitable for self-medication it has received positive response from patient population, clinicians, and pharmaceutical scientists. 
However, factors such as low bioavailability, nasal irritation, and irreversible damage of cilia of cell is expected to hamper the nasal drug delivery market growth.
Segmentation
The global nasal drug delivery market has been segmented into drug type, dosage form, basis of system, delivery technologies, therapeutic applications, end users, and region.
Based on drug type, the global market has been segmented into anesthetics, antibiotics, pain relief drugs, calcium supplements, vasoconstrictors, antihistamines, and others.
Based on dosage form, the global market has been segmented into drops, sprays, powder, gels, and ointments.
Based on the basis of system, the global nasal drug delivery market has been segmented into unit dose, multi-dose, and metered dose.
Based on delivery technologies, the global market has been segmented into spray, nebulizers, inhalers, and others.
Based on therapeutic applications, the global market has been segmented into rhinitis, asthma, nasal congestion, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and others.
The global market, by end user, has been divided into home care settings and hospitals & clinics.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nasal drug delivery market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European nasal drug delivery market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Asia-Pacific nasal drug delivery market has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The nasal drug delivery market in the Middle East & Africa has been segmented into the Middle East and Africa. The increasing development in healthcare infrastructure and growing economy in countries such as Kuwait, Iran, Israel, and Iraq drive the market growth in this region. 
Key Players
GlaxoSmithKline Plc. (UK), AstraZeneca (UK), Pfizer, Inc. (US), Becton Dickson & Company (US), Dr. Reddy’s Laboratories Ltd. (India), Sanofi-Aventis (UK), Merck & Co. (US), Cadila Pharmaceuticals (India), AEGIS THERAPEUTICS LLC (US), Novartis AG (UK) , Johnson & Johnson Services, Inc (US) and 3M COMPANY (US) are some of the key players in the global nasal drug delivery market.
Regional Market Summary
Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global nasal drug delivery market owing to an increasing prevalence of rhinitis, congestion, sinusitis, and respiratory allergic reactions.
Additionally, the well-developed healthcare sector and presence of a large number of medical device companies in this region boosts the market growth. According to the Centers for Disease Control and Prevention January 2017, 30.8 million adults were diagnosed with sinusitis in the US.
Europe is expected to hold the second-largest position in the global nasal drug delivery market. The presence of a large patient population suffering from chronic disorders, increasing technological advancement in the healthcare industry, and growing mergers and acquisitions between healthcare companies drives the market growth in this region.
Alabama Nasal Drug Delivery Association (ADMEA) is a Europe based non-profit organization involved in providing home medical equipment. The presence of such organization in Europe enhances the market growth during the forecasted period.
Asia-Pacific is expected to be fastest-growing region owing to the growing geriatric population and increasing incidences of allergy diseases, which is a common cause of respiratory problems in developing countries.
The Middle East & Africa holds the least share of the market. A majority of the market share of this region is expected to be held by the Middle East due to growing government initiatives for the healthcare sector in this region.
Posted by at No comments:

Cough Syrup Market 2020 Size, Business Research, Revenue, Growth Insights to 2023

Market Scenario:
The Global Cough Syrup Market Statistics expects to register a CAGR of 3.45% to reach USD 5,139.63 million by 2026. Cough syrups are the medication used for the temporary relief of coughs, sneezing, or runny noses due to the common cold, hay fever, or other upper respiratory allergies.
The increasing incidence of respiratory disorders along with the rising air pollution are some of the key factors contributing to the growth of the cough syrup market. Additionally, the growing geriatric population, along with an active pharmaceutical sector, are boosting market growth as aged people are more prone to respiratory disorders. Furthermore, the market is expected to witness lucrative growth due to increasing product developments.
However, product recalls, and the stringent regulatory scenario are hampering the growth of the Cough Syrupmarket size.
Market Dynamics
Rising air pollution is acting as a driver for the growth of the market. Air pollution is a major environment-related health threat that stands as a risk factor for both acute and chronic respiratory diseases. According to a report by the Forum of International Respiratory Societies (FIRS), tobacco smoke, indoor air pollution from burning fuels, and air pollution from traffic and industrial sources are highlighted as the primary contributing factors for most respiratory conditions. World Health Organization (WHO) estimated that 4.3 million deaths per year could be attributed to indoor air pollution. Most diseases and deaths that can be attributed to prolonged exposure to poor indoor air quality occurs primarily in women and children, especially in low-income families. Exposure to indoor smoke used for heating and cooking leads to COPD, lung cancer, and, in children, it causes pneumonia and asthma. This large population affected with respiratory disorders due to air pollution is driving the market for cough syrup market as it is a crucial medicine used for the treatment of such diseases.
Segmentation
The global cough syrup market has been segmented into product type, category, and application. Based on product type, the market has been segregated into combination and individuals. Combination product type has been further classified as dextromethorphan + guaifenesin, guaifenesin + pseudoephedrine, and brompheniramine + pseudoephedrine. The individual product type has been further divided into dextromethorphan, guaifenesin, ambroxol, and codeine. Based on the category, the market has been segmented into cough suppressants and expectorants. And by application, the cough syrup market has been categorized as adults and children.
Regional Analysis
The global cough syrup market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to hold a maximum share of the global cough syrup market, and the regional market is projected to register a CAGR of 3.16% during the forecast period. The presence of significant market players in the region, strategic acquisitions by major players to enhance product portfolio, increasing cases of respiratory disorders, and availability of advanced medications for the treatment of chronic obstructive pulmonary disease (COPD) is expected to drive the market growth in this region to combat these concerns effectively through the use of cough syrups.
Europe accounts for the second-largest, in the global cough syrup market, majorly due to the presence of key players such as Novartis, GlaxoSmithKline, and Reckitt Benckiser Group PLC. The cough syrup market in Europe is expected to be driven by the growth of the pharmaceutical industry in Germany, France, and the UK.
Asia-Pacific is estimated to be the fastest-growing market due to the continuous development in developing countries such as India and China. High prevalence of respiratory disorders due to tobacco smoke, exposure to air pollutants at home and the workplace, vehicular pollution, and indoor air pollution from biological agents related to damp and mold further increase the risk of respiratory disease in children and adults in these countries.
The Middle East & Africa cough syrup market has been segmented into major two regions, the Middle East and Africa. The developed countries in the region, such as the UAE and Saudi Arabia, are the ones with the maximum share of the cough syrup market. The advancing healthcare infrastructure, increasing healthcare expenditure, and increasing per capita disposable incomes of the people in these countries are some reasons leading to the large share of the market in these countries. Africa is the least developed region with limited healthcare resources and facilities for the people. The low growth rate due to less developed and less efficient health systems is hampering the growth of the market.
Key Players
The prominent players in the global cough syrup market are Pfizer, Inc. (US), Novartis AG (Switzerland), Merck KGaA (US), Johnson & Johnson Services, Inc. (US), GlaxoSmithKline PLC (UK), Acella Pharmaceuticals, LLC (US), Procter & Gamble (US), Reckitt Benckiser Group PLC (UK), Abbott (US), and Sanofi (France).
The players operating in the global cough syrup market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
  • In February 2019, Merck invested USD 70 million to expand its research & development (R&D) facility in Billerica, Massachusetts for the development of innovative clinical pipeline products.
  • In July 2018, Johnson & Johnson acquired Zarbee's Naturals, a drug-free children's cough syrup. This enabled the company to broaden its product portfolio globally.
  • In December 2016, Pfizer, Inc., launched a series of products as a line extension under the Corex brand name. The first launch was on December 2016, and subsequent launches were conducted in 2017. These formulations were duly approved by central and state regulators.Bottom of Form
Posted by at No comments:

Veterinary Imaging Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2023

Market Scenario
The Global Veterinary Imaging Market is expected to register a CAGR of 7.14% to reach USD 2167.78 million by 2025. Veterinary imaging is the noninvasive method that helps to diagnose disease by making medical images of the veterinary body. We have various advanced imaging technology used for veterinary patients. Veterinary imaging instruments are used to diagnosis of chronic disease and getting medical images of animals. Notably, the increasing prevalence of zoonotic diseases, significant rise in pet insurance purchases, and increased number of veterinary practitioners are promoting the growth of the veterinary imaging market globally.
The market growth is mainly driven by increasing incidence of zoonotic diseases, increasing expenditure on pet insurance, and technological advancements in veterinary imaging. However, high procedure cost and lack of skilled veterinarians may slow the growth of the market.
Market Dynamics
Increasing expenditure on the pet is driving the growth of the Veterinary Imaging market demand. Pet insurance covers various minor to major medical expenses such as accidents, chronic conditions, wellness, and routine care coverage, medication coverage, diagnostic testing and imaging, others. Though pet insurance does not provide 100% coverage, it reimburses around 80% of the total pet medical expenses. According to the North American Pet Health Insurance Association (NAPHIA), North America’s pet health insurance growth was exceeded by 17.2% from 2014 to 2015. It is also reported that the total number of insured pets reached 1.6 million at the end of 2015.
Pet owners spend a lot on routine vet expenses and surgical vet visits. As per the data suggested by The American Pet Products Association (APPA), around 65% of the US population owns a pet, and the US pet industry expenditure in 2015 was USD 60.3 million, which is exceeded to USD 62.8 million. Thus, with the growing spending on animal healthcare, the demand for veterinary diagnosis and the equipment required for the same will also increase, which boosts the growth and veterinary imaging market size.
Segmentation
The global veterinary imaging market is segmented into product type, animal type, therapeutic area, and end user. On the basis of product type, the market is segmented into instruments, veterinary imaging reagents, and veterinary software. On the basis of animal type, it is segmented into small companion animals and large animals. On the basis of the therapeutic area, the veterinary imaging market segmented into orthopedics and traumatology, cardiology, neurology, and oncology. On the basis of end user, the Veterinary Imaging market segmented into hospitals & clinics, and academic institutes.
Regional Analysis
The global veterinary imaging market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas accounted for the largest market share in 2018, and the regional market is projected to register a CAGR of 7.62% during the forecast period. The larger share is majorly attributed to the growth in adoption of pet animals, increasing veterinary healthcare expenditure, increasing demand for pet insurance, and increasing pet ownership. According to the report published by the American Pet Products Association, from 2017 to 2018, 68% of the US households or 85 million families have a pet.
Europe is the second-largest market for veterinary imaging owing to the presence of large market players, innovative advanced technology, increasing companion animal ownership, and the presence of veterinaries.
The Asia Pacific region accounted the third-largest market owing to the presence of large animal population, increasing disposal income, increasing nuclear families preferring to have pets and increased investments by the American and European market giants in Asian countries such as China and India. India held a share of 15.9% in the Asia-Pacific veterinary imaging market in 2018.
The market in the Middle East and Africa is constrained due to poor development of the animal industry and the low productivity of the maximum breeds in the region.
Key Players
The prominent players in the global veterinary imaging market are Esaote SpA (Italy), GE Healthcare (US), Medical Imaging/IMCO, Inc. (US), BCF (Scotland), Fujifilm Holding Corporation (Japan), Heska Corporation (US), Diagnostic Imaging System, Inc. (US), Canon Inc. (Tokyo), Carestream Health (US), and Merry X-Ray (US).
The players operating in the global veterinary imaging market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
  • In March 2019, Esaote SpA launched the new ultrasound platform MyLabX8 for increasing efficiency of ultrasound machines and to maintain the workflow.
  • In October 2018, GE Healthcare announced a strategic collaboration with SonoSim to encourage education and training about ultrasound devices. This collaboration is likely to help the company to increase its customer base.
  • In June 2018, Fujifilm Holding Corporation acquired Irvine Scientific Sales Company, Inc. for USD 800 million. With this acquisition, Fujifilm is likely to enter into the cell culture media business.
Posted by at No comments:

Cranial Fixation and Stabilization Market Covering Growth Inclinations & Development Strategies until 2023

This cranial fixation and stabilization devices market size can be attributed to the growing healthcare market and the ever-expanding technology market. Advances in these fields have created an environment that is conducive to the development of specialized surgical procedures for traditionally high-risk surgeries.
According to the UN, globally, one in six individuals suffers from a neurological disorder. There are several invasive surgeries that being developed to treat such conditions, requiring cranial fixation and stabilization equipment.
The Global Cranial Fixation and Stabilization Market value is expected to reach USD 2.29 Billion by 2025, registering a CAGR of 8.90%.
SEGMENTATION
By Category
Cranial stabilization equipment is used to secure the head during surgery, while cranial fixation implements are tools required to maintain the structural stability of the head and neck.
  • Cranial Fixation Systems: Cranial fixation covers a wide array of tools and implements such as meshes, flap tube clamps, plates, and screws to be used during surgery. They are used predominantly for affixing bones, securing skin, and enhancing cranial integrity post-surgeries such as craniotomies.
  • Cranial Stabilization Systems: Cranial surgeries are usually very delicate and complex, necessitating the use of equipment to immobilize the head. This is accomplished by the use of cranial stabilization equipment such as skull clamps and horseshoe headrests.
By Product
  • Meshes: The leading market segment as 48% of all cranial injuries are maxillofacial. Over 52% of road accident-related injuries are mandibular fractures that require meshes.
  • Skull Clamps: Ideal for prolonged surgeries that require patient immobilization for long periods with limited soft tissue damage. Used to hold the head firmly in place during surgery.
  • Flap Tube Clamps: Used to attach cranial bones to the cranium during delicate surgeries when only a singular motion can be performed upon the afflicted area.
  • Horseshoe Headrests: Used in cases where head movement is not to be completely restrained and soft tissue damage needs to be minimized.
  • Plates: Used to seal gaping cranial wounds.
  • Screws: Facilitate the attachment of cranial bones.
  • Accessories: Include patient positioning systems and support systems.
By Type
  • Resorbable: Materials that are eventually broken down by the body. The growth of the segment is limited by the high costs of the equipment.
  • Non-Resorbable: These are biocompatible and offer unparalleled rigidity and stability to the cranium. Used extensively in developing countries due to their low costs.
By End User
  • Hospitals: The segment commands the largest share of the global cranial fixation and stabilization market as most cranial surgeries are performed in hospitals. Cranial surgeries require the latest equipment and amenities, along with a high level of expertise, which are offered by hospitals.
  • Ambulatory Surgical Centers: As emergency and temporary patient-stabilization surgeries are performed at these centers, the segment accounts for a small market share, which is somewhat offset by the higher revenue per surgery generated.
  • Others: This segment includes on-site trauma and emergency surgeries. This is a niche segment with growth potential due to the establishment of trauma centers at industrial complexes.
 By Region
  • Americas: Largest regional market, with North America accounting for 55% of the global market share.
  • Asia-Pacific: Fastest growing regional market
  • Europe: Second-largest market
  • Middle East & Africa
Key Players
  • Johnson & Johnson (US)
  • Stryker (US)
  • Ostomed (UK)
  • KLS Martin Group (Germany)
  • Medtronic (US)
  • Integra LifeSciences Corporation (US)
  • Braun Melsungen AG (Germany)
  • Changzhou Huida (China)
  • DePuy Synthes (US)
  • Evonos (Germany)
  • Jeil Medical (South Korea)
  • Medicon (Germany)
  • Micromar (Brazil)
  • NEOS Surgery (Spain)
  • Pro Med Instruments (Germany)
  • Zimmer Biomet (US)
Posted by at No comments:

Over-the-Wire Micro-Guide Catheter Market 2019 - Opportunity, Driving Trends And Deep Study 2023

Over-the-wire Micro Guide Catheter (OTW Micro Guide Catheter) is a thin tubular Medical device inserted into the body for diagnosis or treatments of diseases like cardiovascular, neurovascular, and urology. Specially designed to ease complex procedures, OTW Micro Guide Catheter combining excellent cross-ability and optimal guide-wire support, can effectively treat challenging cases involving tortuous vessels, CTO (chronic total occlusions), bifurcations, and highly stenosed and calcified lesions, giving the high success rate.
OTW Catheters are widely used in cardiovascular applications such as peripheral and coronary interventions and neurovascular interventional applications. The high success rate associated with the use of these catheters further augments its uptake and demand, resultantly driving its market growth.
According to Market Research Future (MRFR)’s global Over-the-wire Micro Guide Catheters market Forecast, the industry is expected to grow at a CAGR of 9.37% during the forecast period (2018–2023).
According to reports published by the Centers for Disease Control and Prevention, the coronary heart disease is the most common type of heart diseases that accounted for the death of about 366,000 people in 2015.
Over-the-wire catheters comparatively make a better choice to treat a brain aneurysm than the rapid exchange catheters owing to their capabilities of extra pushing to enter stenose vessels, and additional support that they provide.
The increasing occurrences of coronary heart diseases, neurovascular diseases, hypertension, and other metabolic disorders, raising awareness for health, advancement in technologies, good healthcare infrastructure, and favorable reimbursement policies are fueling the market growth. 
Regional Analysis
The global over-the-wire micro guide catheters market is segmented into four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa. Americas is the global market leader for over-the-wire Micro-guide catheters. As per the study published in the Surgical Neurology International in 2017, it was found that more than 3% population of the United States equivalent to nearly 10 million individuals have a brain aneurysm. North America commands for the major share of the market whereas; South America show the fastest growth of the market due to the presence of boundless growth opportunities.
Europe OTW Micro Guide Catheter market holds the second position, globally. This is primarily attributable to the increasing prevalence of obesity as well as the increased incidence rate of hypertension and diabetes, which in turn is escalating cardiovascular traumas and cardiac arrest. Each year 15% of deaths in Europe occur due to cardiovascular diseases claims a study conducted by European Society of Cardiology.
The Asia Pacific region is the fastest growing market for the over-the-wire micro guide catheters. The region presents significant growth opportunities for market players as local policy makers continue to restructure the policy framework for the healthcare sector.
Global OTW Micro Guide Catheter Market: Segmentation
The global over-the-wire micro guide catheters market is segmented on the basis of applications and end-users. On the basis of applications, it is segmented into cardiovascular and neurovascular. By the cardiovascular, it is segmented into angiography, angioplasty, peripheral stenting, and others. On the basis of the neurovascular, it is segmented into intracranial aneurysms, percutaneous neurointerventional procedures, and others. Based on end-user the market is segmented into hospitals & clinics, ambulatory surgical centers, research & academic institutes, and others.  
Major Players in the Over-the-wire Micro Guide Catheters Market
Enki – Microtubes, Cardinal Health, DePuy Synthes, Koninklijke Philips N.V, Penumbra Inc., Terumo Europe N.V., Integer Holdings Corporation, Merit Medical Systems Inc., Teleflex Incorporated, Cook Medical, Boston Scientific Corporation, Asahi Intecc Company Limited, and Medtronic plc.
Posted by at No comments:

Age-Related Macular Degeneration Market Definition, Symptoms And Treatments Review 2019

Market scenario:
This MRFR study offers a vivid view of the global age-related macular degeneration AMD market. The study includes an in-depth analysis of macro and micro-economic factors likely to influence the market during the forecast period. It further summarizes the key market opportunities and trends.
The Global Age-Related Macular Degeneration Market insights by MRFR assert, the market expected to register a CAGR of 7.80% to reach USD 11,186.8 Million by 2023. Age-related macular degeneration (AMD) is a chronic irreversible medical condition that results in central vision loss because of damage to the central area of the retina (macula). This condition is majorly categorized as dry age-related macular degeneration and wet age-related macular degeneration.
Growing geriatric population and increasing prevalence of age-related macular degeneration, several branded drugs going off-patent are expected to enhance market growth. However, factors such as high cost associated with AMD, stringent FDA regulations may restrain the market growth during the forecast period.
Key Players
The prominent players in the global age-related macular degeneration market are Novartis AG, Pfizer Inc, F. Hoffmann-La Roche AG, Acucela Inc., Ophthotech Corporation, GlaxoSmithKline PLC, Bayer AG, Rxi Pharmaceuticals, Inc., Regeneron Pharmaceutical Inc., Alimera Sciences Inc., Santen Pharmaceuticals Co., ALLERGAN, and Bausch & Lomb Incorporate.
Market Dynamics
The global age-related macular degeneration market has been primarily driven by growing geriatric population and increasing prevalence of age-related macular degeneration, several branded drugs going off patent. For instance, according to the 2017 statistics suggested by the United Nations, it was estimated that 962 million people aged 60 or above comprise 13% of the global population. Factors such as high cost associated with AMD, stringent FDA regulations may restrain the market growth during the forecast period.
Segmentation
The global age-related macular degeneration market has been segmented into type, stages, age group, treatment, and route of administration. Based on type, the market has been classified as wet age-related macular degeneration (wet AMD) and dry age-related macular degeneration (dry AMD). Dry age-related macular degeneration (dry AMD) held a market share of 2,092.6 USD million in 2017. Based on stages the market has been divided into intermediate-stage age-related macular degeneration, early-stage age-related macular degeneration, late-stage age-related macular degeneration. On the basis of age group, the market has been bifurcated into above 75 years, above 60 years, and 40 years. Based on treatment, the market has been divided into treatment and Diagnosis. Based on the route of administration, the market has been classified as an intravitreal route of administration and intravenous route of administration. Based on the end user, the market has been segmented into hospital & clinics, diagnostic centers, and academic research institutes.
Regional Analysis
The global age-related macular degeneration market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas dominate the global age-related macular degeneration market is owing to the rising ophthalmological disorders and increasing aging population. Nearly 7.3 million people are at significant risk of vision loss due to AMD.
Europe holds the second largest market share due to increasing older population and rising patient population. Additionally, improving government initiatives and increasing healthcare frame along with growing demand for technologically innovative treatment is driving the growth of age-related macular degeneration market in Europe
Asia-Pacific is estimated to be the fastest-growing region in the global age-related macular degeneration as it is developing at a very rapid pace and has shown the emergence of many players. Moreover, rising prevalence of eye disorders, increasing healthcare spending, and multinational companies moving towards the developing nations and setting operational set-ups are likely to drive the growth of the market. Japan held a market share of 23.2% in 2017.
The Middle East & Africa are expected to witness restricted growth due to limited access and healthcare affordability among the population. In the Middle East, the growth of the market is driven by increasing healthcare infrastructure and healthcare expenditure.
Posted by at No comments:
Subscribe to: Posts (Atom)